Transcriptional repression by HDAC3 mediates T cell exclusion from Kras mutant lung tumors
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2317694121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Caroline K McGuire und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Genetics, Northwestern University, Chicago, IL 60611. Hauptthemen laut MEDLINE: Lung Neoplasms, Histone Deacetylases, Proto-Oncogene Proteins p21(ras), Chemokine CXCL10. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Histone Deacetylase 3 (HDAC3) function in vivo is nuanced and directed in a tissue-specific fashion. The importance of HDAC3 in Kras mutant lung tumors has recently been identified, but HDAC3 function in this context remains to be fully elucidated. Here, we identified HDAC3 as a lung tumor cell–intrinsic transcriptional regulator of the tumor immune microenvironment. In Kras mutant lung cancer cells, we found that HDAC3 is a direct transcriptional repressor of a cassette of secreted chemokines, including Cxcl10 . Genetic and pharmacological inhibition of HDAC3 robustly up-regulated this gene set in human and mouse Kras , LKB1 (KL) and Kras , p53 (KP) mutant lung cancer cells through an NF-κB/p65-dependent mechanism. Using genetically engineered mouse models, we found that HDAC3 inactivation in vivo induced expression of this gene set selectively in lung tumors and resulted in enhanced T cell recruitment at least in part via Cxcl10 . Furthermore, we found that inhibition of HDAC3 in the presence of Kras pathway inhibitors dissociated Cxcl10 expression from that of immunosuppressive chemokines and that combination treatment of entinostat with trametinib enhanced T cell recruitment into lung tumors in vivo. Finally, we showed that T cells contribute to in vivo tumor growth control in the presence of entinostat and trametinib combination treatment. Together, our findings reveal that HDAC3 is a druggable endogenous repressor of T cell recruitment into Kras mutant lung tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Genetics, Northwestern University, Chicago, IL 60611.
- NOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA 92037.
- Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla CA 92037.
ORCID-Profile: Susan M Kaech, Reuben J Shaw, Lillian J Eichner
Förderung
- NCI NIH HHS
Zitieren
APA
McGuire, C. K., Meehan, A. S., Couser, E., Bull, L., Minor, A. C., Kuhlmann-Hogan, A., Kaech, S. M., Shaw, R. J., & Eichner, L. J. (2024). Transcriptional repression by HDAC3 mediates T cell exclusion from Kras mutant lung tumors. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2317694121
Vancouver
McGuire CK, Meehan AS, Couser E, Bull L, Minor AC, Kuhlmann-Hogan A, et al. Transcriptional repression by HDAC3 mediates T cell exclusion from Kras mutant lung tumors. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2317694121
BibTeX
@article{McGuire2024,
author = {McGuire, Caroline K and Meehan, Ambryn S and Couser, Evan and Bull, Lois and Minor, Allegra C and Kuhlmann-Hogan, Alexandra and Kaech, Susan M and Shaw, Reuben J and Eichner, Lillian J},
title = {Transcriptional repression by HDAC3 mediates T cell exclusion from Kras mutant lung tumors},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2317694121}
}
EUVIMED